TRGT : Analysis & Opinions

  1. Northera NDA Resubmitted By Chelsea - Analyst Blog

    July 11, 2013
    Chelsea Therapeutics resubmitted a new drug application for Northera.
  2. GW Pharma's Sativex Launched in Italy - Analyst Blog

    July 11, 2013
    GW Pharma announced that Sativex has been launched in Italy.
  3. Positive Data from Emergent's BioThrax - Analyst Blog

    July 11, 2013
    Emergent announced positive results from its phase III study on BioThrax.
  4. BioDelivery Announces $20M Debt Financing - Analyst Blog

    July 10, 2013
    BioDelivery Sciences secured a loan of $20 million from MidCap Financial.
  5. Better Access to VIVUS' Qsymia - Analyst Blog

    July 3, 2013
    VIVUS announced initial availability of Qsymia
  6. Affymetrix Upgraded to Neutral - Analyst Blog

    June 26, 2013
    We have upgraded our recommendation for Affymetrix from Underperform to Neutral.
  7. Alexion 4Q Tops on Both Lines - Analyst Blog

    February 14, 2013
    Alexion Pharmaceuticals Inc.'s (ALXN) fourth quarter 2012 earnings (excluding special items but including stock-based compensation ...
  8. SGEN Narrows Loss, Sales Rise - Analyst Blog

    February 13, 2013
    Seattle Genetics, Inc. (SGEN) reported fourth quarter 2012 net loss per share of 9 cents, narrower than the Zacks Consensus ...
  9. Theravance Narrows Y/Y Loss - Analyst Blog

    February 13, 2013
    Theravance Inc.'s (THRX) fourth quarter 2012 loss of 33 cents per share was narrower than the Zacks Consensus loss estimate ...
  10. UCB, Amgen Discontinue Study - Analyst Blog

    February 12, 2013
    UCB (UCBJF) and Amgen Inc. (AMGN) recently announced their decision to discontinue a phase III program being conducted with ...
  11. Loss at MannKind Wider than Expected - Analyst Blog

    February 12, 2013
    MannKind Corporation's (MNKD) loss of 23 cents per share in the fourth quarter of 2012 was wider than the Zacks Consensus ...
  12. Gilead Closes YM Biosciences Buyout - Analyst Blog

    February 11, 2013
    Recently, Gilead Sciences, Inc. (GILD) completed its acquisition of Canada-based drug development company, YM BioSciences ...
  13. Lannett Beats, Ups Guidance - Analyst Blog

    February 11, 2013
    Lannett Company, Inc. (LCI) reported second quarter fiscal 2013 earnings of 10 cents per share, above the Zacks Consensus ...
  14. US Approval for Celgene's Pomalyst - Analyst Blog

    February 11, 2013
    The US Food and Drug Administration (FDA) recently delivered encouraging news to Celgene Corporation (CELG) by approving ...
  15. Loss Widens at Alnylam, Sales Fall - Analyst Blog

    February 8, 2013
    Alnylam Pharmaceuticals Inc.'s (ALNY) fourth quarter 2012 loss of $1.20 per share was narrower than the Zacks Consensus Estimate ...
  16. Vivus Unveils Qsymia Study Results - Analyst Blog

    February 7, 2013
    Vivus Inc. (VVUS) recently announced the publication of results from a study regarding its weight-loss drug, Qsymia. Results ...
  17. Kalydeco Funding Cleared in Ireland - Analyst Blog

    February 6, 2013
    Vertex Pharmaceuticals Inc. (VRTX) recently announced that the Health Service Executive (HSE) in the Republic of Ireland ...
  18. Good News for UCB - Analyst Blog

    February 6, 2013
    Good news flowed in at UCB (UCBJF) from Europe when the European Union (EU) approved Vimpat (lacosamide) as a single loading ...
  19. Alnylam-MDCO Join for ALN-PCS - Analyst Blog

    February 5, 2013
    Alnylam Pharmaceuticals Inc. (ALNY) recently entered into an exclusive global alliance with The Medicines Company (MDCO) ...
  20. Canada Approves Seattle Genetics' Adcetris - Analyst Blog

    February 4, 2013
    Seattle Genetics Inc. (SGEN) recently received approval from Health Canada for its oncology drug, Adcetris (brentuximab vedotin). ...
  21. Alkermes Turns to Profit, Ups View - Analyst Blog

    February 1, 2013
    Alkermes plc (ALKS) reported earnings of 14 cents per share in the third quarter of fiscal 2013 (ended December 31, 2012). ...
  22. 4Q Revenues Decline at Vertex - Analyst Blog

    January 30, 2013
    Vertex Pharmaceuticals Inc. (VRTX) posted a loss of 9 cents per share (including stock-based compensation expense) in the ...
  23. Cadence Forecasts Ofirmev Sales - Analyst Blog

    January 25, 2013
    Cadence Pharmaceuticals Inc. (CADX) recently announced that it expects preliminary net revenue of Ofirmev (acetaminophen) ...
  24. Sales Rise at Celgene - Analyst Blog

    January 24, 2013
    Celgene Corporation's (CELG) fourth quarter 2012 earnings (excluding special items but including stock-based compensation ...
  25. InterMune Prices Public Offerings - Analyst Blog

    January 18, 2013
    InterMune Inc. (ITMN) recently priced its concurrent underwritten public offerings of convertible senior notes and shares ...
  26. AMRN Aims to Fortify Vascepa Patent - Analyst Blog

    January 17, 2013
    Amarin Corporation plc (AMRN), recently announced that the notice of patent allowance for US application serial number 13/61 ...
  27. InterMune to Raise Funds - Analyst Blog

    January 16, 2013
    InterMune Inc. (ITMN) recently announced its intention to raise funds through concurrent underwritten public offerings. InterMune ...
  28. Loss Widens at IRWD on Higher Costs - Analyst Blog

    January 16, 2013
    Ironwood Pharmaceuticals, Inc.'s (IRWD) fourth-quarter 2012 loss of 41 cents per share compared unfavorably with the year-ago ...
  29. Alnylam to Raise $125 Million - Analyst Blog

    January 15, 2013
    Alnylam Pharmaceuticals Inc. (ALNY) recently began an underwritten public offering of shares of its common stock. Alnylam ...
  30. Aegerion Upbeat About 2013 - Analyst Blog

    January 8, 2013
    Aegerion Pharmaceuticals Inc. (AEGR) recently announced its 2013 guidance as the company prepares for the launch of Juxtapid, ...
  31. Pipeline Update from Alnylam - Analyst Blog

    January 8, 2013
    Alnylam Pharmaceuticals Inc (ALNY) recently announced its goal for the next two years (2013 and 2014) regarding its key "Alnylam ...
  32. Positive Data on Alkermes Candidate - Analyst Blog

    January 4, 2013
    Alkermes plc (ALKS) recently announced positive results from a phase I study on its new antipsychotic candidate, ALKS 3831. ...
  33. Coronado Amends Ovamed Agreement - Analyst Blog

    January 3, 2013
    Coronado Biosciences (CNDO) recently amended its existing license and supply agreements with Ovamed GmbH. Coronado now has ...
  34. FDA Approves Aegerion's Juxtapid - Analyst Blog

    December 26, 2012
    The US Food and Drug Administration (FDA) recently approved Aegerion Pharmaceuticals' (AEGR) Juxtapid (lomitapide) capsules. ...
  35. ALIOF Drug to Move into Phase III - Analyst Blog

    December 26, 2012
    Actelion (ALIOF) recently announced that it is moving forward with phase III development of cadazolid in patients suffering ...
Investing News
  1. Thoughts From The Frontline: Every Central Bank For Itself

    Thoughts from the Frontline: Every Central Bank for Itself
  2. 3 Dumb Ways to Borrow Money

    Money — everyone needs it, but not everyone has it. Many people who find themselves in a ...
  3. Infographic - The Lifecycle of a Bond

    Basic information on how Bonds work.
  4. What $200,000 Will Buy In The Atlanta Real Estate Market

    Atlanta housing prices are up from last year, but they're still lower than the national median. ...
  5. Bubble Bursting? Only For Biotech & Internet Stocks

    The recent sluggish performance of U.S. stocks is leading some market watchers to question ...
  6. What $300,000 Will Buy In The Riverside/San Bernardino Real Estate Market

    The median list price for the San Bernardino/Riverside, Calif. market is $292,800, up 24.6% ...
Trading Center